Therapeutic Asset Ratings

515 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Acalabrutinib Heart Failure	AstraZeneca	P4	B (62)
Cyclophosphamide Heart Failure	AstraZeneca	P4	B (62)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER Heart Failure	AstraZeneca	P4	B (62)
Inno-206 Heart Failure	AstraZeneca	P4	B (62)
PREDNISONE TABLETS Heart Failure	AstraZeneca	P4	B (62)
(+)-VINCRISTINE Heart Failure	AstraZeneca	P4	B (62)
su011248 Papillary Renal Cell Carcinoma	AstraZeneca	P3	B (62)
su011248 Urologic Neoplasms	AstraZeneca	P3	B (62)
VOLITINIB Carcinoma	AstraZeneca	P3	B (62)
Abemaciclib High-grade Serous Ovarian Cancer (HGSOC)	AstraZeneca	P2	B (62)
Durvalumab Clear Cell Renal Cell Carcinoma	AstraZeneca	P2	B (62)
Surovatamig B-cell Non-Hodgkin Lymphoma	AstraZeneca	P2	B (62)
azd6244 Non Small Cell Lung Cancer	AstraZeneca	P3	B (61)
CIS-DIAMMINEDICHLOROPLATINUM II Esophageal Squamous Cell Carcinoma	AstraZeneca	P3	B (61)
Acalabrutinib B-Cell Non-Hodgkin Lymphoma	AstraZeneca	P2	B (61)
Cediranib Advanced Tumor	AstraZeneca	P2	B (61)
Durvalumab Melanoma	AstraZeneca	P2	B (61)
1H-BENZIMIDAZOLE, 2-(((4-(3-METHOXYPROPOXY)-3-METHYL-2-PYRIDINYL)METHYL)SULFINYL)-, SODIUM SALT, HYDRATE (1:1:1) Metastatic Castration-Sensitive Prostate Cancer	AstraZeneca	P3	B (60)
Abemaciclib ER-Positive HER2-Negative Breast Cancer	AstraZeneca	P3	B (60)
Arimidex ER-Positive HER2-Negative Breast Cancer	AstraZeneca	P3	B (60)
Camizestrant ER-Positive HER2-Negative Breast Cancer	AstraZeneca	P3	B (60)
Elecoglipron Weight Management	AstraZeneca	P3	B (60)
Eplontersen Transthyretin Amyloid Cardiomyopathy	AstraZeneca	P3	B (60)
Folic Acid Non Small Cell Lung Cancer	AstraZeneca	P3	B (60)
FULVESTRANT ER-Positive HER2-Negative Breast Cancer	AstraZeneca	P3	B (60)

Showing 51 to 75 of 515 assets

PreviousPage 3 of 21Next